Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Five Clinical Trial Misses Of 2023

Jan 09 2024

• By Alexandra Shimmings

man missing target — • Source: Shutterstock

Related Content

Sanofi Falls Further Behind In Cancer

Dec 21 2023

Lack Of Efficacy, Not Safety, Dooms Merck KGaA’s BTK Inhibitor

Dec 06 2023

Bayer Buffeted By OCEANIC Setback

Nov 20 2023

FibroGen’s Roxadustat On The Rocks After Phase III Myelodysplastic Syndrome Failure

May 05 2023

FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF

Jun 27 2023

FibroGen Adrift After Yet Another Pamrevlumab Failure

Aug 30 2023

Sarepta And Roche Press Ahead With Elevidys Filing Despite Duchenne Trial Miss

Oct 31 2023

FibroGen Misses In First Of Two Pivotal DMD Trials

Jun 07 2023

Sarepta Confident Of Full US Approval For Duchenne Gene Therapy By Mid-2024

Jan 09 2024

Bayer Sees Significant, But Smaller, Asundexian Opportunity

Jan 09 2024

Related Companies

Bayer AG

Merck KGaA

Sanofi

Roche Holding AG

Novartis AG

Sarepta Therapeutics, Inc.

FibroGen, Inc.

Additional Topics

Clinical Trials Companies Research & Development Scrip Perspectives Cancer Metabolic Disorders Blood & Coagulation Disorders Neurology Respiratory BioPharmaceutical

More from Scrip Perspectives

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window